A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1028 | Th1005 | Etanercept | LPAQVAFTPYAPEPGSTCRL Full view | 255 | IIa | Immunological | Enbrel | Immunex Corp | Lyophilized powder. | Subcutaneous injection | Immunosuppressive Agents | Tumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
| 1029 | Th1005 | Etanercept | LPAQVAFTPYAPEPGSTCRL Full view | 255 | IIa | Immunological | Enbrel Sureclick | N.A. | Solution | Subcutaneous injection | Immunosuppressive Agents | Tumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
| 1038 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Eligard | Atrix Labs/QLT In | Suspension | Subcutaneous Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1039 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Enantone | Takeda | Solution | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1040 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Leuplin | Takeda | N.A. | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1041 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | LeuProMaxx | Baxter/Teva | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1042 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Leupromer | N.A. | N.A. | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1043 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Lupron | Abbott/TAP Pharmaceuticals | N.A. | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1044 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Lutrate | N.A. | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1045 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Memryte | Curaxis | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1046 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Prostap 3 | Takeda UK Limited | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1047 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Prostap SR | Takeda UK Limited | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1048 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Viadur | Bayer AG | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1180 | Th1023 | Anakinra | MRPSGRKSSKMQAFRIWDVN Full view | 153 | IIa | Immunological | Kineret | Amgen Inc | Sterile, clear, colorless-to-white, preservative free solution | Subcutaneous (SC) administration | Immunosuppressive Agents, Anti-rheumatic agents | Interleukin-1 receptor type 1 |
| 1187 | Th1024 | Gramicidin D | VGALAVVVWLWLWLWX Full view | 16 | IIa | Infectious | Neosporin | Pfizer | Ointment | External use only | Anti-Bacterial Agents, Anti-infective, Topical, Antibiotic | N.A. |
| 1188 | Th1024 | Gramicidin D | VGALAVVVWLWLWLWX Full view | 16 | IIa | Infectious | Sofradex | Sanofi | Sterile, clear, bright, colourless, aqueous solution | Auricular and Ocular use. | Anti-Bacterial Agents, Anti-infective, Topical, Antibiotic | N.A. |
| 1265 | Th1038 | Omalizumab | Heavy chain:EVQLVESG Full view | 243 | IIa | Immunological | Xolair | Genentech Inc | Sterile, white, preservative free, lyophilized powde | Subcutaneous Injection | Anti-Allergic Agents, Anti-asthmatic, Immuno-suppressive agents | High affinity immunoglobulin epsilon receptor subunit alpha and beta |
| 1327 | Th1046 | Abciximab | H ReoPro-like antibo Full view | 218 | IIa | Genetic/Metabolic/Haemetological | ReoPro | Eli Lilly and Company | Clear, colorless, sterile, non-pyrogenic solution | Intravenous administartion | Platelet Aggregation Inhibitors, Anticoagulants | Integrin beta-3,Integrin alpha-IIb,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immuno |
| 1331 | Th1047 | Alpha-1-proteinase inhibitor | EDPQGDAAQKTDTSHHDQDH Full view | 255 | IIa | Metabolic/Geneti/Respiratory | Aralast | Baxter | Lyophilized powder | Intravenous infusion | Serine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | Neutrophil elastase |
| 1332 | Th1047 | Alpha-1-proteinase inhibitor | EDPQGDAAQKTDTSHHDQDH Full view | 255 | IIa | Metabolic/Geneti/Respiratory | Prolastin | Talecris Biotherapeutics C formerly Bayer | Lyophilized powder | Intravenous infusion | Serine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | Neutrophil elastase |
| 1368 | Th1054 | Infliximab | N.A. Full view | 0 | IIa | Immunological | REMICADE | Centocor Inc | Sterile, white, lyophilized powder, following reconstitution with 10 mL of Sterile Water for Injection, USP, the resulting pH is approximately 7.2. | Intravenous infusion | Antirheumatic Agents, Anti-Inflammatory Agents, Non-Steroidal, Dermatologic Agents, Gastrointestinal Agents and Immunosuppressive Agents | Tumor necrosis factor |
| 1385 | Th1061 | Trastuzumab | Light chain 1: DIQMT Full view | 1364 | IIa | Cancer | Herceptin | Genentech | Sterile, white to pale yellow, preservative-free lyophilized powder |  Intravenous administration | Antineoplastic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Insulin-degrading enzyme,HLA class II histocompatibility antigen, DQ alpha 2 chain,HLA class II histocompatibility antigen, DQ beta 1 chain,Retinoblastoma-associated protein,Cathepsin D,Carboxypeptidase E,Neuroendocrine convertase 2,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-related protein 2,Insulin-like growth factor-binding protein 7,Synaptotagmin-like protein 4 |
| 1389 | Th1062 | Rituximab | Heavy Chain: QVQLQQP Full view | 664 | IIa | Cancer/Immunological | Rituxan | Biogen Idec Inc., and Genentech USA, Inc | Sterile, clear, colorless, preservative-free liquid concentrate |  Intravenous administration | Antineoplastic Agents, Immunologic Factors and Antirheumatic Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Receptor tyrosine-protein kinase erbB-2,Epidermal growth factor receptor,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor I |
| 1398 | Th1063 | Basiliximab | Heavy Chain: QLQQSGT Full view | 657 | IIa | Immunological | Simulect | Novartis | Sterile lyophilisate which is available in 6 mL colorless glass vials and is available in 10 mg and 20 mg strength | intravenous infusion mainly or bolus (if no allergic reactions occurs) | Immunosuppressive Agents | N.A. |
| 1400 | Th1064 | Muromonab | Heavy Chain: QVQLQQS Full view | 664 | IIa | Immunological | ORTHOCLONE OKT3 STERILE SOLUTION | Centocor Ortho Biotech, L.P. | Sterile Solution is a murine monoclonal antibody to the CD3 antigen of human T cells which functions as an immunosuppressant. | For Intravenous Use Only | Immunologic Factors and Immunosuppressive Agents | N.A. |
| 1403 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DIGIBIND | Galaxo Smith Kline | Sterile lyophilized powder of antigen binding fragments (Fab) derived from specific antidigoxin antibodies raised in sheep. | Intravenous infusion after reconstitution with Sterile Water for Injection | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1404 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DigiFab |  Protherics Inc | Sterile, purified, lyophilized preparation of digoxin-immune ovine Fab (monovalent) immunoglobulin fragments. | Intravenous administration | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1409 | Th1067 | Daptomycin | N.A. Full view | 0 | IIa | Infectious | CUBICIN | Cubist Pharmaceuticals, Inc | Sterile, preservative-free, pale yellow to light brown, lyophilized cake containing approx 500 mg of daptomycin | Intravenous(IV) Injection | N.A. | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1415 | Th1069 | Pegvisomant | FPTIPLSRLFDNAMLRAHRL Full view | 191 | IIa | Hormonal | SOMAVERT | Pfizer | Sterile, white lyophilized powder | Subcutaneous Injection | Hormone Replacement Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1431 | Th1073 | Alemtuzumab | Heavy Chain 1: QVQLQ Full view | 2839 | IIa | Cancer | CAMPATH | Genzyme Corporation | Sterile, clear, colorless, isotonic solution (pH 6.8-7.4) | Intravenous infusion | N.A. | N.A. |
| 1432 | Th1073 | Alemtuzumab | Heavy Chain 1: QVQLQ Full view | 2389 | IIa | Cancer | LEMTRADA | Genzyme Corporation | LEMTRADA is a sterile, clear and colorless to slightly yellow, solution (pH 7.2±0.2) for infusion. | Intravenous infusion | NA | NA |
| 1442 | Th1078 | Efalizumab | Light Chain:DIQMTQSP Full view | 229 | IIa | Immunological | RAPTIVA | Genentech, Inc. | Sterile, white to off-white, lyophilized powder in single-use glass vials | Subcutaneous injection. | Immunosuppressive Agents | Iduronic acid |
| 1449 | Th1081 | Antithymocyte Globulin | N.A. Full view | 0 | IIa | Immunological | Antithymocyte globulin | Pfizer | N.A. | Intravenous infusion | Immunologic Factors and Immunosuppressive Agents | N.A. |
| 1462 | Th1088 | Enfuvirtide | YTSLIHSLIEESQNQQEKNE Full view | 36 | IIa | Infectious | `FUZEON | Trimeris, Roche | White to off-white, sterile, lyophilized powder. | Subcutaneous injection | HIV Fusion Inhibitors | Oxytocin receptor,Oxytocin-neurophysin 1, Envelope glycoprotein |
| 1466 | Th1090 | Daclizumab | QVQLVQSGAEVKKPGSSVKV Full view | 674 | IIa | Immunologicals | Zenapax | Roche | Clear, sterile, colorless concentrate for further dilution and intravenous administration | Intravenous injection | Immunosuppressive Agents | Fusion glycoprotein F0,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1468 | Th1091 | Bevacizumab | DIQMTQSPSSLSASVGDRVT Full view | 214 | IIa | Cardiac | Avastin | Genentech | Slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion | Intravenous infusion | Angiogenesis Inhibitors | Interleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1474 | Th1094 | Panitumumab | N.A. Full view | 0 | IIa | Cancer | Vectibix | Amgen Inc | Sterile, colorless, pH 5.6 to 6.0 liquid for intravenous (IV) infusion, which may contain a small amount of visible translucent-to-white, amorphous, proteinaceous, panitumumab particulates | N.A. | N.A. | Epidermal growth factor receptor |
| 1475 | Th1095 | Ranibizumab | Light Chain SASQDISN Full view | 447 | IIa | Hematological/Eye Disorder | Lucentis | Genentech | Sterile, colorless to pale yellow solution | Intravitreal injection | Ophthalmics | Vascular endothelial growth factor A |
| 1495 | Th1102 | Abatacept | MHVAQPAVVLASSRGIASFV Full view | 357 | IIa | Immunological | ORENCIA | Bristol-Myers Squibb | Lyophilized powder, supplied as a sterile, white, preservative-free, lyophilized powder for intravenous administration | Intravenous infusion and Subcutaneous injection | Antirheumatic Agents and Immunosuppressive Agents | T-lymphocyte activation antigen CD80,T-lymphocyte activation antigen CD86 |
| 1529 | Th1108 | Pegaptanib | N.A. Full view | 0 | IIa | Hematological/Eye Disorder | Macugen | Gilead Sciences | Sterile, aqueous solution containing pegaptanib sodium for intravitreous injection | Intravitreal injection | Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. | N.A. |
| 1533 | Th1112 | Natural Alpha Interferon Or Multiferon | Inteferon alpha-1: | 997 | IIa | Cancer/Infectious | Intron/ Roferon-A | N.A. | N.A. | Subcutaneous injection, Intravenous injection, Intramuscular injection | N.A. | N.A. |
| 1534 | Th1113 | Glatiramer Acetate | EAYKAAEKAYAAKEAAKEAA Full view | 52 | IIa | Neurological Disorder | Copaxone | Teva Pharmaceutical Industries | Clear, colorless to slightly yellow, sterile, nonpyrogenic solution | Subcutaneous injection | N.A. | N.A. |
| 1536 | Th1115 | Teicoplanin | N.A. Full view | 0 | IIa | Infectious | Targocid | NPS Pharmaceuticals | Light yellow solid | Intravenous injection, Intramuscular injection | Anti-Bacterial Agents | D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan |
| 1550 | Th1119 | Tocilizumab | N.A. Full view | 0 | IIa | Immunological | ACTEMRA | Genentech | Sterile, preservative-free solution, colorless to pale yellow liquid, with a pH of about 6.5 | Intravenous infusion, Subcutaneous injection | N.A. | Interleukin-6 receptor subunit alpha |
| 1562 | Th1122 | Rilonacept | rilonacept|Homo sapi Full view | 880 | IIa | Immunological | Arcalyst | Regeneron Pharmaceuticals | Sterile, white to off-white, lyophilized powder | Subcutaneous injection | Immunosuppressive Agents | Interleukin-1 beta,Interleukin-1 alpha,Interleukin-1 receptor antagonist protein |
| 1596 | Th1126 | Belatacept | MHVAQPAVVLASSRGIASFV Full view | 357 | IIa | Immunological | Nulojix | Bristol-Myers Squibb | Sterile, white or off-white lyophilized powder | Intravenous injection | Antirheumatic Agents and Immunosuppressive Agents | T-lymphocyte activation antigen CD86,T-lymphocyte activation antigen CD80 |
| 1609 | Th1132 | Belimumab | N.A. Full view | 0 | IIa | Immunological | Benlysta | GlaxoSmithKline | Sterile, white to off-white, preservative-free, lyophilized powder | Intravenous infusion | Monoclonal antibodies | Tumor necrosis factor ligand superfamily member 13B |
| 1627 | Th1138 | Raxibacumab | N.A. Full view | 0 | IIa | Immunological/Infectious | RAXIBACUMAB | GSK | Sterile, liquid formulation in single-dose vials | N.A. | Anti-Infective Agents and Monoclonal antibodies | Protective antigen |
| 1644 | Th1147 | Natalizumab | N.A. Full view | 0 | IIa | Genetic/Immunological | Tysabri | Biogen Idec Inc. | Sterile, colorless, and clear to slightly opalescent concentrate | Intravenous infusion | Immunosuppressive agents | N.A. |
| 1648 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekturna | Physicians Total Care, Inc. | Light-pink, biconvex round tablet | Oral route | Renin inhibitor | Renin |